Information Provided By: 
Fly News Breaks for April 27, 2015
CLDN, QURE
Apr 27, 2015 | 08:55 EDT
Roth Capital said it would be opportunistic buyers of uniQure (QURE) shares if the stock is weak following the failure of a trial for competitor Celladon's (CLDN) gene therapy for heart failure patients, Mydicar. The firm believes uniQure's S100A1 target in its trial is potentially superior to the one used in Celladon's study and the firm thinks uniQure's pipeline is "at the cusp" of significant value creation. Roth reiterates its Buy rating and $38 price target on uniQure shares.
News For QURE;CLDN From the Last 2 Days
There are no results for your query QURE;CLDN
